Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-752-1300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees147
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Personalis (NASDAQ:PSNL) Frequently Asked Questions
What is Personalis' stock symbol?
Personalis trades on the NASDAQ under the ticker symbol "PSNL."
How were Personalis' earnings last quarter?
Personalis (NASDAQ:PSNL) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.89) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.58. The firm earned $15.80 million during the quarter, compared to the consensus estimate of $14.92 million. The business's quarterly revenue was up 79.5% on a year-over-year basis. View Personalis' Earnings History.
When is Personalis' next earnings date?
What guidance has Personalis issued on next quarter's earnings?
Personalis issued an update on its FY 2019 earnings guidance on Tuesday, August, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $60-62 million, compared to the consensus revenue estimate of $59.07 million.
What price target have analysts set for PSNL?
5 brokerages have issued twelve-month target prices for Personalis' stock. Their predictions range from $27.00 to $29.00. On average, they expect Personalis' share price to reach $28.25 in the next twelve months. This suggests a possible upside of 49.8% from the stock's current price. View Analyst Price Targets for Personalis.
What is the consensus analysts' recommendation for Personalis?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Personalis.
Has Personalis been receiving favorable news coverage?
Press coverage about PSNL stock has trended positive recently, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Personalis earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for Personalis.
Who are some of Personalis' key competitors?
Some companies that are related to Personalis include Natera (NTRA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Fulgent Genetics (FLGT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), Cancer Genetics (CGIX) and First Choice Healthcare Solutions (FCHS).
What other stocks do shareholders of Personalis own?
Who are Personalis' key executives?
Personalis' management team includes the folowing people:
- Mr. John West, Co-Founder, CEO, Pres & Director (Age 62)
- Prof. Russ B. Altman M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
- Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board
- Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
- Dr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
When did Personalis IPO?
(PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager.
When did the company's quiet period expire?
Personalis' quiet period expired on Tuesday, July 30th. Personalis had issued 7,921,500 shares in its IPO on June 20th. The total size of the offering was $134,665,500 based on an initial share price of $17.00. During the company's quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
Who are Personalis' major shareholders?
Personalis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Board of Trustees of The Leland Stanford Junior University (4.80%), JPMorgan Chase & Co. (2.13%), Janus Henderson Group PLC (1.68%), Janus Henderson Group PLC (1.68%), Laurion Capital Management LP (1.05%) and Orbimed Advisors LLC (1.01%). View Institutional Ownership Trends for Personalis.
Which institutional investors are buying Personalis stock?
PSNL stock was acquired by a variety of institutional investors in the last quarter, including Board of Trustees of The Leland Stanford Junior University, JPMorgan Chase & Co., Janus Henderson Group PLC, Janus Henderson Group PLC, Laurion Capital Management LP, Orbimed Advisors LLC, Price T Rowe Associates Inc. MD and Nicholas Investment Partners LP. View Insider Buying and Selling for Personalis.
How do I buy shares of Personalis?
Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Personalis' stock price today?
One share of PSNL stock can currently be purchased for approximately $18.86.
How big of a company is Personalis?
What is Personalis' official website?
How can I contact Personalis?
Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]
MarketBeat Community Rating for Personalis (NASDAQ PSNL)
MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote "Outperform" if you believe PSNL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days.
